Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D
NCT03899883Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2020
- Primary completion
- Apr 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegloticase in type 2 diabetes mellitus (T2DM) and hyperuricemia, sponsored by University of Colorado Denver. Primary endpoints: Systolic Blood Pressure at 1 week, Diastolic Blood Pressure at 1 week and 6 more. Started Jan 2020; status: completed.
02
Drugs
pegloticase
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on NCT03899883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899883.